Petra De Geest

Business Unit Manager Medical Affairs

12 years of experience in the medical device field. Expert in clinical evidence and medical writing for Class I to Class III devices, including MDSW and AI-driven MDSW, as well as safety management in clinical investigations.

3 articles

Regulatory AffairsApr 15, 2026 1 min

Home Market Approval ≠ EU Readiness

FDA or NMPA approval doesn't mean EU readiness. Learn why home market success often leads to delays under EU MDR, and how to avoid them.

Regulatory AffairsSep 4, 2025 2 min

PMCF: How QbD Group Helps You Master MDR Compliance from Plan to Report

Discover how QbD supports MDR compliance with strategic PMCF planning, execution, and documentation, from plan to report.

ClinicalMar 5, 2025 10 min

Post-Market Surveillance (PMS) and Post-Market Clinical Follow-Up (PMCF) under the MDR: Ensuring safety and performance

With the introduction of the Medical Device Regulation (MDR), the requirements for placing medical devices on the market have significantly increased. Additional manufacturers’ obligations concerning post-market surveillance (PMS), including post-market clinical follow-up (PMCF), have gained importance.

We use cookies to enhance your experience

We use essential cookies for site functionality and optional analytics cookies to improve our services. Read our Privacy Policy and Cookie Policy.